Anthropic unveils Claude Life Sciences to transform research efficiency
The new Claude Life Sciences platform supports researchers from hypothesis creation to regulatory reporting, cutting manual work and promoting responsible AI use in biotechnology.
Anthropic has unveiled Claude for Life Sciences, its first major launch in the biotechnology sector.
The new platform integrates Anthropic’s AI models with leading scientific tools such as Benchling, PubMed, 10x Genomics and Synapse.org, offering researchers an intelligent assistant throughout the discovery process.
The system supports tasks from literature reviews and hypothesis development to data analysis and drafting regulatory submissions. According to Anthropic, what once took days of validation and manual compilation can now be completed in minutes, giving scientists more time to focus on innovation.
An initiative that follows the company’s appointment of Eric Kauderer-Abrams as head of biology and life sciences. He described the move as a ‘threshold moment’, signalling Anthropic’s ambition to make Claude a key player in global life science research, much like its role in coding.
Built on the newly released Claude Sonnet 4.5 model, which excels at interpreting lab protocols, the platform connects with partners including AWS, Google Cloud, KPMG and Deloitte.
While Anthropic recognises that AI cannot accelerate physical trials, it aims to transform time-consuming processes and promote responsible digital transformation across the life sciences.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!
